MRC-Holland MLPA. Description version 29;
|
|
- Angel Stanley
- 5 years ago
- Views:
Transcription
1 SALSA MLPA KIT P003-B1 MLH1/MSH2 Lot 1209, As compared to the previous lots 0307 and 1006, one MLH1 probe (exon 19) and four MSH2 probes have been replaced. In addition, one extra MSH2 exon 1 probe, two extra EPCAM (=TACSTD1) probes and two extra control fragments at 100 and 105 nt have been included. Germ-line defects in the DNA mismatch repair genes MSH2 and MLH1 are the major cause of hereditary nonpolyposis colon cancer (HNPCC; Lynch syndrome). Detection of the germ-line defect in HNPCC families allows identification of relatives who require appropriate surveillance and prevents useless surveillance in noncarrier relatives. A significant percentage of the HNPCC germ-line mutations are genomic deletions of one or more exons of the MLH1 and MSH2 genes (Wijnen J.T. et al (1998) Nature Genet. 20: ). In a study in which 126 colorectal cancer families were screened, a germ-line mutation was detected in 30% of the families (Gille, J.J.P. et al (2002) British J. of Cancer 87, ). Deletions of one or more MLH1/MSH2 exons were detected with the use of this P003 MLPA kit, and accounted for 46% of all mutations detected. Many studies have shown that genomic rearrangements of MLH1 and MSH2 are also an important cause of HNPCC in other countries. In the study of Gille et al, copy number changes of one or more exons were detected in 17 out of 126 families (13.5%). However, this percentage will depend on the way the cohort is selected. The MLH1 gene contains 19 exons and spans 100 kb on chromosome 3p22.1. The MSH2 gene contains 16 exons and covers 73 kb on chromosome 2p21. The P003 probemix contains probes for each of the 19 exons of the MLH1 gene, for each of the 16 exons of the MSH2 gene. From version B1 onwards, two probes are included for the most 3 exon of EPCAM (formerly known as TACSTD1), a gene located just upstream of MSH2. Deletions of the most 3 exon of EPCAM can result in silencing of the MSH2 gene (Ligtenberg M.J.L. et al. (2009) Nature Genet. 41: ). Finally, 7 probes for other human genes located on different chromosomes are included for reference purposes. This SALSA kit is designed to detect deletions/duplications of one or more sequences in the MLH1 and MSH2 genes and the most 3 exon of EPCAM in a DNA sample. Heterozygous deletions of recognition sequences should give a 35-50% reduced relative peak area of the amplification product of that probe. Note that a mutation or polymorphism in the sequence detected by a probe can also cause a reduction in relative peak area, even when not located exactly on the ligation site! In addition, some probe signals are more sensitive to sample purity and small changes in experimental conditions. Therefore, deletions and duplications detected by MLPA should always be confirmed by other methods. Not all deletions and duplications detected by MLPA will be pathogenic; users should always verify the latest scientific literature when interpreting their findings. We have no information on what percentage of defects in these genes is caused by deletions/duplications of complete exons. Finally, note that most defects in this gene are expected to be small (point) mutations which will not be detected by this SALSA test. SALSA kits are sold by for research purposes and to demonstrate the possibilities of the MLPA technique. This kit is not CE/FDA certified for use in diagnostic procedures. SALSA MLPA kits are supplied with all necessary buffers and enzymes. Purchase of the SALSA MLPA test kits includes a limited license to use these products for research purposes. The use of this SALSA kit requires a thermocycler with heated lid and sequence type electrophoresis equipment. Different fluorescent PCR primers are available. The MLPA technique has been first described in Nucleic Acid Research 30, e57 (2002). Related SALSA MLPA kits P248 MLH1/MSH2: Recommended for confirmation of deletions / duplications detected by the P003 kit. P072 MSH6: Contains probes for MSH6, MUTYH, MLH1 and MSH2 upstream regions. P008 PMS2: Contains probes for the complicated PMS2 gene. ME011 Mismatch Repair genes (MMR): Methylation profiling of MLH1, MSH2, MSH6, PMS2 and MGMT. P043 APC: Hereditary polyposis colon cancer, gene included APC More information Website : info@mlpa.com (information & technical questions); order@mlpa.com (for orders) Mail : bv; Willem Schoutenstraat 6, 1057 DN Amsterdam, the Netherlands SALSA kit P003 MLH1-MSH2 Page 1 of 6
2 References for SALSA MLPA kit P003 Aissi-Ben Moussa, S. et al (2009). Identification and characterization of a novel MLH1 genomic rearrangement as the cause of HNPCC in a Tunisian family: evidence for a homologous Alu-mediated recombination. Fam Cancer 8 (2): Stella A. et al. (2007). Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC. Clin Genet Feb;71(2): Pistorius S. et al. (2006). Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations. Cancer Lett Jul 10. Niesen RC et al. (2006). Identification of mismatch repair gene mutations in young colorectal cancer patients and patients with multiple HNPCC-associated tumours. Gut Apr 24 Zhang J et al. (2006). Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from MLH1/MSH2 deletion carriers. Cancer Res Jan 15;66(2): Grabowski, M. et al. (2005). Deletions Account for 17% of Pathogenic Germline Alterations in MLH1 and MSH2 in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Families. Genet Test. 9(2): Wehner, M. et al. (2005). Hereditary nonpolyposis colorectal cancer: pitfalls in deletion screening in MSH2 and MLH1 genes. Eur J Hum Genet May 4. McVety et al. (2005). Novel genomic insertion-deletion in MLH1: possible mechanistic role for non-homologous endjoining DNA repair. Clin Genet Sep;68(3): Ainsworth, P.J. et al. (2004). Family cancer histories predictive of a high risk of hereditary non-polyposis colorectal cancer associate significantly with a genomic rearrangement in hmsh2 or hmlh1. Clin. Genet. 66: Bunyan DJ et al. (2004). Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer 13;91(6): Taylor, C.F. et al. (2003) Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: identification of novel and recurrent deletions by MLPA. Human Mutation 22: Nakagawa, H. et al. (2003). Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch Syndrome (HNPCC) by novel techniques. Human Mutation 22: 258. Gille, J.J. et al. (2002). Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br. J. Cancer 87: Data analysis The P003-B1 MLH1-MSH2 probemix contains 46 different MLPA probes with amplification products between 130 and 490 nt. In addition, it contains 9 control fragments generating an amplification product smaller than 120 nt: four DNA Quantity fragments (Q-fragments) at nt, three DNA denaturation control fragments (D-fragments) at nt, one X-fragment at 100 nt and one Y-fragment at 105 nt. More information on how to interpret observations on these control fragments can be found in the MLPA protocol. Data generated by this probemix can first be normalised intra-sample by dividing the peak area of each probe s amplification product by the total area of only the reference probes in this probemix (block normalisation). Secondly, inter-sample normalisation can be achieved by dividing the intra-normalised probe ratio in a sample by the average intra-normalised probe ratio of all reference samples. Please note that this type of normalisation assumes no changes occurred in the genomic regions recognised by the reference probes Data normalisation should be performed within one experiment. Only samples purified by the same method should be compared. Confirmation of most exons deletions and amplifications can be done by e.g. Southern blotting or long range PCR. Note that Coffalyser, the MLPA analysis tool developed at, can be downloaded free of charge from our website mrna analysis We do not recommend the use of this probemix for the analysis of MLH1 and MSH21 mrnas/cdna, although it is possible. The MSH2 exon 11 probe is directed to the strand present in U The MLH1 exon 18 probe is directed to the strand present in U These probes will not detect cdna. All other probes are directed to the complement of NM_ /NM_ and most will bind to cdna. However, some probes extent to within an intron sequence and may not bind to cdna as efficiently as they do to DNA. As the ligation site of probe MLH1 exon 16 is one nucleotide in front of the start of this exon, it will certainly not bind to cdna. Complete probe sequences are available upon request. This probemix was developed by. Info/remarks/suggestions for improvement: info@mlpa.com SALSA kit P003 MLH1-MSH2 Page 2 of 6
3 Table 1. SALSA MLPA P003-B1 MLH1 / MSH2 probemix Length Chromosomal position SALSA MLPA probe (nt) reference MLH1 MSH Q-fragments: DNA quantity; only visible with less than 100 ng sample DNA D-fragments: Low signal of 88 or 96 nt fragment indicates incomplete denaturation 100 X-fragment: Specific for the X chromosome 105 Y-fragment: Specific for the Y chromosome 130 Reference probe L q Reference probe L p MLH1 probe L00474 Exon * MSH2 probe L02162 Exon MLH1 probe L00577 Exon MSH2 probe L00494 Exon MLH1 probe L00476 Exon MSH2 probe L00601 Exon MLH1 probe L00477 Exon MSH2 probe L00496 Exon * MSH2 probe L12006 Exon Reference probe L p MLH1 probe L06064 Exon MSH2 probe L00497 Exon * MSH2 probe L14624 Exon MLH1 probe L14625 Exon ± MSH2 probe L00498 Exon MLH1 probe L00480 Exon * MSH2 probe L12398 Exon MLH1 probe L00481 Exon MSH2 probe L00582 Exon MLH1 probe L00482 Exon Reference probe L q MSH2 probe L00583 Exon MLH1 probe L00483 Exon * MSH2 probe L12007 Exon MLH1 probe L00484 Exon MSH2 probe L00503 Exon MLH1 probe L00485 Exon MSH2 probe L00504 Exon MLH1 probe L00486 Exon MSH2 probe L00575 exon Reference probe L q MLH1 probe L00586 exon MSH2 probe L00506 Exon MLH1 probe L00488 Exon MSH2 probe L00585 Exon MLH1 probe L00576 Exon MSH2 probe L14623 Exon MLH1 probe L00602 Exon MLH1 probe L00603 Exon * MLH1 probe L12994 Exon Reference probe L p * EPCAM probe L14404 upstream 481 * EPCAM probe L03603 upstream 490 * Reference probe L q12 * New in version P003-B1 (from lot 0109 onwards) Changed in version B1 (from lot 0109 onwards). Small change in length. No change in sequence detected. ± SNP rs may influence probe signal. In case of apparent deletions, sequence probe s target region. The 337 nt MLH1 exon 12 has been found to give false deletions, the occurrence of which may be dependent on the SALSA kit P003 MLH1-MSH2 Page 3 of 6
4 extraction method used. The exon 12 probe in the P248 MLPA probemix does not have this problem and can be used for confirmation. Note: The identity of the genes detected by the reference probes is available on request: Table 2. P003 probes arranged according to chromosomal location Table 2a. MLH1 gene Length (nt) SALSA MLPA probe MLH1 exon Ligation site NM_ Partial sequence (24 nt adjacent to ligation site) Distance to next probe startcodon L00474 exon CCAAAATGTCGT-TCGTGGCAGGGG 3.1 Kb L00577 exon GATTCAGATCCA-AGACAATGGCAC 4.3 Kb L00476 exon TGCAGTCCTTTG-AGGATTTAGCCA 3.4 Kb L00477 exon CATAAGCCATGT-GGCTCATGTTAC 2.6 Kb L06064 exon AAACCATGTGCT-GGCAATCAAGGG 1.8 Kb L14625 exon TGGAGGACCTTT-TTTACAACATAG 3.0 Kb L00480 exon ACACAATGCAGG-CATTAGTTTCTC 0.2 Kb L00481 exon TGTTAGGACACT-ACCCAATGCCTC 2.4 Kb L00482 exon CCTAGCCTTCAA-AATGAATGGTTA 3.1 Kb L00483 exon TTCCTTGAGAAA-AGCCATAGAAAC 2.9 Kb L00484 exon GCAGCACATCGA-GAGCAAGCTCCT 5.5 Kb L00485 exon AGGCAGCAAGAT-GAGGAGATGCTT 3.0 Kb L00486 exon TCCCGAAAGGAA-ATGACTGCAGCT 11.4 Kb L00586 exon CGTGGGCTGTGT-GAATCCTCAGTG 2.1 Kb L00488 exon CCAGATACTCAT-TTATGATTTTGC 5.3 Kb L00576 exon CATGCTTGCCTT-AGATAGTCCAGA 1.0 Kb L00602 exon ATCTTCATTCTT-CGACTAGCCACT 0.4 Kb L00603 exon reverse CTCCTCAGATAT-GTACTGCTTCCG 1.8 Kb 454 * L12994 exon reverse TATCAGAAGGCA-AGTATAAGTCTT stopcodon * New in version P003-B1 (from lot 0109 onwards) Changed in version B1 (from lot 0109 onwards). Small change in length. No change in sequence detected. Note: The MLH1 exon numbering in Table 2a is different as compared to the new exon numbering that is used by the NCBI in the NM_ reference sequence! We used the same exon numbering as in all previous versions of this product description. Complete probe sequences are available on request: info@mlpa.com. Please notify us of any mistakes: info@mlpa.com. SALSA kit P003 MLH1-MSH2 Page 4 of 6
5 Table 2b. MSH2 gene Length (nt) SALSA MLPA probe MSH2 exon Ligation site Partial sequence (24 nt adjacent to ligation site) Distance to next probe NM_ EPCAM stopcodon ** L03603 EPCAM exon AAATGGACACAA-ATTACAAATGTG 0.1 Kb 472 ** L14404 EPCAM exon reverse GGTCAAATTTCA-AGATTGGTAAAG 16.0 Kb to MSH2 NM_ startcodon * L14624 exon nt before ATG startcodon CCGGGCACATTA-CGAGCTCAGTGC 0.2 Kb 148 * L02162 exon nt before ATG startcodon GCGTGCGCGGGA-AGCTGGGCCGCG 0.7 Kb 190 * L12006 exon nt after exon 1 reverse GAACTAGAACAA-TGCATTAAAATG 4.8 Kb L00494 exon TATAGAGTTGAA-GTTTATAAGAAT 1.7 Kb L00601 exon TTGTGGGTGTTA-AAATGTCCGCAG 2.3 Kb L00496 exon CGGTTGTTGAAA-GGCAAAAAGGGA 1.8 Kb L00497 exon ACTGTCTGCGGT-AATCAAGTTTTT 2.1 Kb L00498 exon GCCTTGCTGAAT-AAGTGTAAAACC 13.5 Kb 247 * L12398 exon AGACAAGCAGCA-AACTTACAAGAT 15.7 Kb L00582 exon CTCCTCTTACTG-ATCTTCGTTCTG 17.5 Kb L00583 exon AATTCCTTGTAA-AACCTTCATTTG 3.9 Kb 310 * L12007 exon nt after exon 10 GACTGAAGTGGT-ACTTTGGGTCTA 4.0 Kb L00503 exon reverse GCTTCTTCATAT-TCTGTTTTATTT 4.1 Kb L00504 exon CACCTGTTCCAT-ATGTACGACCAG 1.3 Kb L00575 exon TCATGGCCCAAA-TTGGGTGTTTTG 1.9 Kb L00506 exon CCTACGATGGAT-TTGGGTTAGCAT 2.5 Kb L00585 exon ACTTGAGGAGTT-TCAGTATATTGG 2.0 Kb L14623 exon GTGTTTCAGCAA-GGTGAAAAAATT stopcodon * New in version P003-B1 (from lot 0109 onwards) Changed in version B1 (from lot 0109 onwards). Small change in length. No change in sequence detected. ** The 481 nt EPCAM (=TACSTD1) probe detects the same sequence as the 190 nt probe in P008 PMS2 and the 310 nt probe in P072-B1 MSH6. This probe might be influenced by the RS polymorphism. Simultaneous deletion of the 472 and 481 nt probes is a strong indication that the last EPCAM exon (exon 9) is disrupted, which can lead to methylation and inactivation of MSH2 (Ligtenberg M.J.L. et al.(2009) Nature Genet. 41: ). More probes for EPCAM are available in SALSA MLPA kit P072 MSH6. We recommend usage of SALSA MLPA kit ME011 MMR to test the methylation status of the MSH2 promoter and of other mismatch repair genes. Note: Exon numbering might be different as compared to literature! Complete probe sequences are available on request: info@mlpa.com. Please notify us of any mistakes: info@mlpa.com. SALSA kit P003 MLH1-MSH2 Page 5 of 6
6 SALSA MLPA kit P003-B1 MLH1-MSH2 sample picture ,77 128,12 145, ,40 182,90 237,99 229,45 328, ,48 202,65 223,79 216, ,97 141,18 165,28 344,03 105, ,21 90,71 195,74 189,00 176,59 210,38 246,49 256,21 263,18 301,96 291,10 283,46 319,18 310,68 352,47 401,53 408,23 391,42 427,69 454,78 482,29 472, ,10 272,84 335,03 363,89 374,82 444, ,37 382,32 419,15 436,63 462,57 492, Dye Signal Size (nt) Figure 1. Capillary electrophoresis pattern from a sample of approximately 50 ng human male control DNA analyzed with SALSA MLPA kit P003-B1 MLH1-MSH2 (lot 1209). Implemented Changes the following has been altered compared to the previous product description version(s). Version 29 (45) - Warning added about the possible presence of a SNP in the target sequence of the prober targeting exon 6 of MSH2. Version 28 (45) - Product description adapted to a new lot (lot number added, small changes in Table 1 and Table 2, new picture included). - Small changes of probe lengths in Table 1 and 2 in order to better reflect the true lengths of the amplification products. - Ligation sites updated according to new version of the NM_reference sequence. - Warning added below Table 2a that the MLH1 exon numbering used is different from the NCBI exon numbering in the NM_ mrna reference sequence. Version 27 (45) - Reference added of Aissi-Ben Moussa, S. et al (2009). Minor textual and layout changes. Version 26 (44) - Minor changes in the product description on page 1 and in the data analysis section on page 2. - Minor changes on table titles. SALSA kit P003 MLH1-MSH2 Page 6 of 6
MRC-Holland MLPA. Description version 08; 30 March 2015
SALSA MLPA probemix P351-C1 / P352-D1 PKD1-PKD2 P351-C1 lot C1-0914: as compared to the previous version B2 lot B2-0511 one target probe has been removed and three reference probes have been replaced.
More informationMRC-Holland MLPA. Description version 18; 09 September 2015
SALSA MLPA probemix P090-A4 BRCA2 Lot A4-0715, A4-0714, A4-0314, A4-0813, A4-0712: Compared to lot A3-0710, the 88 and 96 nt control fragments have been replaced (QDX2). This product is identical to the
More informationNew: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.
SALSA MLPA KIT P045-B2 BRCA2/CHEK2 Lot 0410, 0609. As compared to version B1, four reference probes have been replaced and extra control fragments at 100 and 105 nt (X/Y specific) have been included. New:
More informationMRC-Holland MLPA. Description version 29; 31 July 2015
SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0114. As compared to the previous B2 version (lot 0813 and 0912), 11 target probes are replaced or added, and 10 new reference probes are included. P082
More informationMRC-Holland MLPA. Description version 30; 06 June 2017
SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0517, C1-0114. As compared to the previous B2 version (lot B2-0813, B2-0912), 11 target probes are replaced or added, and 10 new reference probes are
More informationMRC-Holland MLPA. Description version 12; 13 January 2017
SALSA MLPA probemix P219-B3 PAX6 Lot B3-0915: Compared to version B2 (lot B2-1111) two reference probes have been replaced and one additional reference probe has been added. In addition, one flanking probe
More informationSALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted.
mix P169-C2 HIRSCHSPRUNG-1 Lot C2-0915. As compared to version C1 (lot C1-0612), the length of one has been adjusted. Hirschsprung disease (HSCR), or aganglionic megacolon, is a congenital disorder characterised
More informationMRC-Holland MLPA. Description version 14; 28 September 2016
SALSA MLPA probemix P279-B3 CACNA1A Lot B3-0816. As compared to version B2 (lot B2-1012), one reference probe has been replaced and the length of several probes has been adjusted. Voltage-dependent calcium
More informationSALSA MS-MLPA KIT ME011-A1 Mismatch Repair genes (MMR) Lot 0609, 0408, 0807, 0407
SALSA MS-MLPA KIT ME011-A1 Mismatch Repair genes (MMR) Lot 0609, 0408, 0807, 0407 The Mismatch Repair (MMR) system is critical for the maintenance of genomic stability. MMR increases the fidelity of DNA
More informationSALSA MLPA KIT P050-B2 CAH
SALSA MLPA KIT P050-B2 CAH Lot 0510, 0909, 0408: Compared to lot 0107, extra control fragments have been added at 88, 96, 100 and 105 nt. The 274 nt probe gives a higher signal in lot 0510 compared to
More informationSALSA MLPA probemix P241-D2 MODY mix 1 Lot D As compared to version D1 (lot D1-0911), one reference probe has been replaced.
mix P241-D2 MODY mix 1 Lot D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent diabetes
More informationMRC-Holland MLPA. Description version 08; 18 November 2016
SALSA MLPA probemix P122-D1 NF1 AREA Lot D1-1016. As compared to lot C2-0312, four probes in the NF1 area and one reference probe have been removed, four reference probes have been replaced and several
More informationSALSA MLPA probemix P241-D2 MODY mix 1 Lot D2-0716, D As compared to version D1 (lot D1-0911), one reference probe has been replaced.
mix P241-D2 MODY mix 1 Lot D2-0716, D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent
More informationSALSA MLPA KIT P060-B2 SMA
SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the
More informationMRC-Holland MLPA. Description version 19;
SALSA MLPA probemix P6-B2 SMA Lot B2-712, B2-312, B2-111, B2-511: As compared to the previous version B1 (lot B1-11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). SPINAL
More informationMRC-Holland MLPA. Description version 07; 26 November 2015
SALSA MLPA probemix P266-B1 CLCNKB Lot B1-0415, B1-0911. As compared to version A1 (lot A1-0908), one target probe for CLCNKB (exon 11) has been replaced. In addition, one reference probe has been replaced
More informationSALSA MLPA probemix P315-B1 EGFR
SALSA MLPA probemix P315-B1 EGFR Lot B1-0215 and B1-0112. As compared to the previous A1 version (lot 0208), two mutation-specific probes for the EGFR mutations L858R and T709M as well as one additional
More informationMRC-Holland MLPA. Description version 06; 23 December 2016
SALSA MLPA probemix P417-B2 BAP1 Lot B2-1216. As compared to version B1 (lot B1-0215), two reference probes have been added and two target probes have a minor change in length. The BAP1 (BRCA1 associated
More informationMRC-Holland MLPA. Description version 08; 07 May 2015
mix P185-C1 Intersex Lot C1-0611: As compared to the previous version B2 (lot B2-0311), s for CYP21A2 have been removed and s for the CXorf21 gene as well as additional s for NR0B1, NR5A1 and the Y chromosome
More informationSALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B
SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B1-0613. The purpose of the P372 probemix is to further investigate results found with the P245 Microdeletion Syndromes-1A probemix. The
More informationSALSA MLPA probemix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four probes have been adjusted.
mix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four s have been adjusted. The sex-determining region on chromosome Y (SRY) is the most important
More informationSALSA MLPA probemix P371-A1 Microdeletion Syndromes 5 Lot A1-0509
mix P371-A1 Microdeletion Syndromes 5 Lot A1-0509 The purpose of the P371 mix is to further investigate results found with the P245 Microdeletion mix. The P245 mix provides a possibility to screen samples
More informationP323-B1 CDK4-HMGA2-MDM2
SALSA MLPA probemix P323-B1 CDK4-HMGA2-MDM2 Lot B1-0714, B1-0711. As compared to previous test version (lot A1-0508), this probemix has been completely redesigned. Probes for HMGA2 and several other genes
More informationMRC-Holland MLPA. Description version 06; 07 August 2015
SALSA MLPA probemix P323-B1 CDK4-HMGA2-MDM2 Lot B1-0711. As compared to version A1 (test version sent to test labs), this product has been completely redesigned. Probes for HMGA2 and several other genes
More informationMost severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment).
SALSA MLPA probemix P343-C3 Autism-1 Lot C3-1016. As compared to version C2 (lot C2-0312) five reference probes have been replaced, one reference probe added and several lengths have been adjusted. Warning:
More informationMRC-Holland MLPA. Description version 13;
SALSA MLPA probemix P027-C1 Uveal Melanoma Lot C1-0211: A large number of probes have been replaced by other probes in the same chromosomal regions as compared to previous lots, and several reference probes
More informationSALSA MLPA probemix P360-A1 Y-Chromosome Microdeletions Lot A
SALSA MLPA probemix P360-A1 Y-Chromosome Microdeletions Lot A1-1011. This SALSA MLPA probemix is for basic research and intended for experienced MLPA users only! This probemix enables you to quantify genes
More informationMRC-Holland MLPA. Related SALSA MLPA probemixes P190 CHEK2: Breast cancer susceptibility, genes included: CHEK2, ATM, PTEN, TP53.
SALSA MLPA probemix P056-C1 TP53 Lot C1-0215 & lot C1-0214. As compared to version B1 (lot B1-1011) most of the reference and flanking probes have been replaced and several have been added. Furthermore,
More informationMRC-Holland MLPA. Description version 28; 4 January 2018
SALSA MLPA probemix ME011-B3 Mismatch Repair genes Lot B3-1017 and B3-0715. As compared to the previous version B2 (lot B2-0614), one probe has a small change in length but no change in the sequence detected.
More informationPRADER WILLI/ANGELMAN
SALSA MS-MLPA probemix ME028-B2 PRADER WILLI/ANGELMAN Lot B2-0811: As compared to version B1 (lot B1-0609, B1-1108), the 88 and 96 nt control fragments have been replaced (QDX2). PRADER-WILLI SYNDROME
More informationSALSA MLPA KIT P078-B1 Breast Tumour Lot 0210, 0109
SALSA MLPA KIT P078-B1 Breast Tumour Lot 0210, 0109 This P078-B1 Breast Tumour probemix contains probes for several genes (including ERBB2, BIRC5, MYC, TOP2A, ESR1, MTDH, CCND1, CCNE1, EGFR and C11orf30)
More informationSALSA MLPA Probemix P014-B1 Chromosome 8 Lot B and B
SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B1-0916 and B1-0713. Copy number changes of the human chromosome 8 are common in many types of tumours. In most cases, losses of 8p sequences and gains of 8q
More informationMRC-Holland MLPA. Description version 52; 22 July 2015
SALSA MS-MLPA probemix ME028-B2 Prader-Willi/Angelman Lot B2-0413, lot B2-0811. As compared to version B1 (lot B1-0609), the control fragments have been replaced (QDX2). PRADER-WILLI SYNDROME (PWS) and
More informationSALSA MLPA probemix P383-A1 T-ALL Lot A
SALSA MLPA probemix P383-A1 T-ALL Lot A1-0213. T-lineage acute lymphoblastic leukaemia (T-ALL) is a clonal malignant disorder of immature T-cells, which accounts for about 15% of paediatric and 25% of
More informationMRC-Holland MLPA. Description version 23; 15 February 2018
SALSA MLPA probemix P225-D2 PTEN Lot D2-0315. As compared to the previous version (lot D1-0613), one probe has a small change in length but no change in the sequence detected. PTEN is a tumour suppressor
More informationSALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length.
SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length. This SALSA probemix is for basic research only! This
More informationMRC-Holland MLPA. Description version 05; 03 April 2019
SALSA MLPA probemix ME012-A1 MGMT-IDH1-IDH2 Lot A1-1215. Glioblastoma, the most common malignant primary brain tumour, is characterised by aggressive behaviour and a poor survival. Hypermethylation in
More informationProduct Description SALSA MS-MLPA Probemix ME011-C1 Mismatch Repair Genes To be used with the MS-MLPA General Protocol.
Product Description SALSA MS- Probemix ME011-C1 Mismatch Repair Genes To be used with the MS-MLPA General Protocol. Version C1. As compared to the previous version (lot B3-1017), this probemix has been
More informationProduct Description SALSA MLPA probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol.
Product Description SALSA probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol. Version C1. As compared to version B3, the probes for the BRCA2 upstream region and exons 8, 11, 12, 19
More informationProduct Description SALSA MLPA Probemix P055-D1 PAH To be used with the MLPA General Protocol.
Product Description SALSA Probemix P055-D1 PAH To be used with the MLPA General Protocol. Version D1. For complete product history see page 7. Catalogue numbers: P055-025R: SALSA MLPA probemix P055 PAH,
More informationProduct Description SALSA MLPA Probemix P027-C2 Uveal melanoma To be used with the MLPA General Protocol.
Product Description SALSA Probemix P027-C2 Uveal melanoma To be used with the MLPA General Protocol. Version C2. As compared to version C1, three reference probes have been replaced and the lengths of
More informationMRC-Holland MLPA. Description version 23; 26 January 2017
SALSA MLPA probemix ME024-B2 9p21 CDKN2A/2B region Lot B2-0615. As compared to the previous version B1 (lot B1-0411), one flanking probe is redesigned, two reference probes are replaced, and several probes
More informationMRC-Holland MLPA. Description version 10; 06 April 2018
Description version ; 6 April 8 mix P36-B Y-Chromosome Microdeletions Lot B-5. As compared to version A (Lot A-), all probes f DPY9L, one probe f RBMYCP and one probe f KDM5D have been removed, and one
More informationProduct Description SALSA MLPA Probemix P138-C1 SLC2A1-STXBP1 To be used with the MLPA General Protocol.
Product Description SALSA Probemix P138-C1 SLC2A1-STXBP1 To be used with the MLPA General Protocol. Version C1. For complete product history see page 7. Catalogue numbers: P138-025R: SALSA MLPA probemix
More informationProduct Description SALSA MLPA Probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol.
Product Description SALSA Probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol. Version C1. As compared to version B3, the probes for the BRCA2 upstream region and exons 8, 11, 12, 19
More informationProduct Description SALSA MS-MLPA Probemix ME028-C1 Prader-Willi/Angelman To be used with the MS-MLPA General Protocol.
Product Description SALSA MS- Probemix ME028-C1 Prader-Willi/Angelman To be used with the MS-MLPA General Protocol. Version C1. For complete product history see page 9. Catalogue numbers: ME028-025R: SALSA
More informationMRC-Holland MLPA. Description version 15;
probemix P036-E1 HUMAN TELOMERE-3 Lot E1-0910, E1-1208, E1-0808. As compared to version D2 (lot D2-0408), the probes for 1p and 4q have been replaced. Approximately 3-8% of all cases of mental retardation
More informationSALSA MLPA KIT P036-E1 HUMAN TELOMERE-3 Lot 0808: As compared to the previous version (P036-D2), the probes for 1p and 4q have been replaced.
SALSA MLPA KIT P036-E1 HUMAN TELOMERE-3 Lot 0808: As compared to the previous version (P036-D2), the probes for 1p and 4q have been replaced. MENTAL RETARDATION is caused by aberrant copy numbers of subtelomeric
More informationLynch Syndrome and COLARIS Testing
Lynch Syndrome and COLARIS Testing Webinar Objectives Review of Lynch syndrome as a multi-gene disorder COLARIS Enhancements Technical Overview COLARIS test offerings Test development and validation process
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
More informationAbstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction
Optimization strategy of Copy Number Variant calling using Multiplicom solutions Michael Vyverman, PhD; Laura Standaert, PhD and Wouter Bossuyt, PhD Abstract Copy number variations (CNVs) represent a significant
More informationProduct Description SALSA MLPA probemix P002-D1 BRCA1 To be used with the MLPA General Protocol.
Product Description SALSA probemix P002-D1 BRCA1 To be used with the MLPA General Protocol. Version D1. As compared to version C2, 12 extra BRCA1 probes and 3 probes for exon 24 have been included, and
More informationProduct Description SALSA MLPA Probemix P002-D1 BRCA1 To be used with the MLPA General Protocol.
Product Description SALSA Probemix P002-D1 BRCA1 To be used with the MLPA General Protocol. Version D1. For a complete product history see page 11. Catalogue numbers: P002-025R: SALSA MLPA probemix P002
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationProduct Description SALSA MLPA Probemix P015-F2 MECP2 To be used with the MLPA General Protocol.
Product Description SALSA Probemix P015-F2 MECP2 To be used with the MLPA General Protocol. Version F2. Compared to version F1, two reference probes have been replaced and the 118 nt Y fragment has been
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationCOLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014
COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 WENDY MCKINNON, MS, CGC CERTIFIED GENETIC COUNSELOR FAMILIAL CANCER PROGRAM UNIVERSIT Y OF VERMONT MEDICAL CENTER 1 CHARACTERISTICS
More informationTumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer
TumorNet-Lynch genetic testing for hereditary colorectal or uterine cancer What Are the Causes of Hereditary Colorectal Cancer? sporadic 70% familial 20% hereditary 10% Lynch syndrome, up to 4% Familial
More informationTumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in
SAMPLE REPORT Ordered By Contact ID:1251298 Example, Doctor, MD MOCKORG44 (10829) 123 Somewhere LaneSuite 4 Heaven NV 78872 US Ph:123-123-1234 Fx:123-123-1223 Org ID:8141 Normal Specimen Accession #: 00-086947
More informationDeletions Account for 17% of Pathogenic Germline Alterations in MLH1 and MSH2 in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Families ABSTRACT
GENETIC TESTING Volume 9, Number 2, 2005 Mary Ann Liebert, Inc. Deletions Account for 17% of Pathogenic Germline Alterations in MLH1 and MSH2 in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Families
More informationLynch Syndrome. Angie Strang, PGY2
Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system
More informationLYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)!
LYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)! Kathryn Singh, MPH, MS, LCGC Associate Clinical Professor Assistant Director, Graduate Program in Genetic Counseling Division of Genetic and Genomic
More informationYes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationGENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome
GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By HENRY T. LYNCH, M.D. 1 Could this be hereditary Colon Cancer 4 Creighton University School of Medicine Omaha, Nebraska Magnitude of the Problem Annual
More informationCANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease)
CANCER Affects 25% of US population Kills 19% of US population (2nd largest killer after heart disease) NOT one disease but 200-300 different defects Etiologic Factors In Cancer: Relative contributions
More informationCase Study. Overview. Deleterious MLH1 mutation detected on sequencing 10/16/2014
The Role of Next Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Endometrial Cancer Laura J. Tafe, MD Assistant Professor of Pathology Assistant Director, Molecular Pathology Dartmouth-Hitchcock
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationMolecular biology of colorectal cancer
Molecular biology of colorectal cancer Phil Quirke Yorkshire Cancer Research Centenary Professor of Pathology University of Leeds, UK Rapid pace of molecular change Sequencing changes 2012 1,000 genomes
More informationCode CPT Descriptor Test Purpose and Method Crosswalk Recommendation SEPT9 (Septin9) (e.g., colorectal cancer) methylation analysis
ASSOCIATION FOR MOLECULAR PATHOLOGY Education. Innovation & Improved Patient Care. Advocacy. 9650 Rockville Pike. Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7995 amp@amp.org www.amp.org August
More informationStudying The Role Of DNA Mismatch Repair In Brain Cancer Malignancy
Kavya Puchhalapalli CALS Honors Project Report Spring 2017 Studying The Role Of DNA Mismatch Repair In Brain Cancer Malignancy Abstract Malignant brain tumors including medulloblastomas and primitive neuroectodermal
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: 2.04.08 Last Review: 1/2018 Origination: 1/2004 Next Review: 1/2019 Policy Blue Cross and Blue Shield of Kansas
More informationSupplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our
1 2 Supplemental Data: Detailed Characteristics of Patients with MKRN3 Mutations 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Patient 1 was born after an uneventful pregnancy. She presented
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationContent. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome
of Lynch Syndrome: guidelines 17/03/2009 Content Terminology Lynch Syndrome Presumed Lynch Syndrome Familial Colorectal Cancer Identification of Lynch Syndrome Amsterdam II criteria Revised Bethesda Guidelines
More informationDIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE DIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document Molecular testing strategies for Lynch syndrome in The National Institute for Health
More informationIntroduction to Cancer Biology
Introduction to Cancer Biology Robin Hesketh Multiple choice questions (choose the one correct answer from the five choices) Which ONE of the following is a tumour suppressor? a. AKT b. APC c. BCL2 d.
More informationGenetic Testing for Inherited Susceptibility to Colon Cancer; Including Microsatellite Instability Testing. Original Policy Date
MP 2.04.06 Genetic Testing for Inherited Susceptibility to Colon Cancer; Including Microsatellite Instability Testing Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review
More informationUsing the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep
Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep Tom Walsh, PhD Division of Medical Genetics University of Washington Next generation sequencing Sanger sequencing gold
More informationA Review from the Genetic Counselor s Perspective
: A Review from the Genetic Counselor s Perspective Erin Sutcliffe, MS, CGC Certified Genetic Counselor Cancer Risk Evaluation Program INTRODUCTION Errors in base pair matching that occur during DNA replication,
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationGEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics
GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics The Medical/Surgical/Radiation Oncologist s View of Genetics Cancer
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: Original Effective Date: MM.02.007 09/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration
More informationCélia DeLozier-Blanchet
The Genetics Consultation in OB-GYN : Hereditary cancers Célia DeLozier-Blanchet Division of Medical Genetics, Geneva University Hospital It is probable that all cancers are genetic! genetic vs. hereditary
More informationResource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)
Putting NICE guidance into practice Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27) Published: February 2017 Summary Molecular testing strategies
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationStability of BAT26 in tumours of hereditary nonpolyposis colorectal cancer patients with MSH2 intragenic deletion
(2006) 14, 63 68 & 2006 Nature Publishing Group All rights reserved 1018-4813/06 $30.00 www.nature.com/ejhg ARTICLE Stability of BAT26 in tumours of hereditary nonpolyposis colorectal cancer patients with
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationCANCER GENETICS PROVIDER SURVEY
Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationGenetic Testing for Lynch Syndrome
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post-test genetic counseling is
More informationOriginal Policy Date
MP 2.04.76 Genetic Counseling Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created Local Policy/ 12:2013 Return to Medical Policy Index Disclaimer
More informationThe molecular genetics of colorectal cancer
1 Department of Gastroenterology, North Middlesex University Hospital, London, UK 2 Institute of Molecular Genetics, Cardiff University 3 Department of Gastroenterology, Queen s Hospital Romford, London,
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: 2.04.08 Last Review: 1/2019 Origination: 1/2004 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Genetic Testing for Lynch Syndrome and Other Inherited Page 1 of 34 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Testing for Lynch Syndrome and Other
More informationGenetic testing all you need to know
Genetic testing all you need to know Sue Clark Consultant Colorectal Surgeon, St Mark s Hospital, London, UK. Colorectal cancer Familial 33% Polyposis syndromes
More informationPrior Authorization. Additional Information:
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationHereditary non polyposis colorectal cancer in a random sample of colorectal cancer patients
Basic Science Hereditary non polyposis colorectal cancer in a random sample of colorectal cancer patients Nada Pavlović-Čalić 1, Izet Eminović 2, Vesna Hadžiabdić 3, Kasim Muminhodžić 1, Radovan Komel
More information